These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22648661)

  • 1. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
    Vittone F; Liberman A; Vasic D; Ostertag R; Esser M; Walcher D; Ludwig A; Marx N; Burgmaier M
    Diabetologia; 2012 Aug; 55(8):2267-75. PubMed ID: 22648661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
    Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
    PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
    Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
    Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
    Zeng Y; Li C; Guan M; Zheng Z; Li J; Xu W; Wang L; He F; Xue Y
    Cardiovasc Diabetol; 2014 Feb; 13():32. PubMed ID: 24490809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
    Marques C; Mega C; Gonçalves A; Rodrigues-Santos P; Teixeira-Lemos E; Teixeira F; Fontes-Ribeiro C; Reis F; Fernandes R
    Mediators Inflamm; 2014; 2014():538737. PubMed ID: 24817793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
    J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
    Dobrian AD; Ma Q; Lindsay JW; Leone KA; Ma K; Coben J; Galkina EV; Nadler JL
    Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E410-21. PubMed ID: 21081706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.
    Burgmaier M; Liberman A; Möllmann J; Kahles F; Reith S; Lebherz C; Marx N; Lehrke M
    Atherosclerosis; 2013 Dec; 231(2):427-35. PubMed ID: 24267262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin exerts an antinflammatory action.
    Makdissi A; Ghanim H; Vora M; Green K; Abuaysheh S; Chaudhuri A; Dhindsa S; Dandona P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3333-41. PubMed ID: 22745245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
    Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
    Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
    Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
    Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.